A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Gallium-68-OncoCAIX-Philogen (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms OncoCAIX
- Sponsors Philogen
- 26 Feb 2025 New trial record